Skip to Main Content

Clinical Role and Cost-Effectiveness of Long-Acting ART

2015

Long-acting antiretroviral therapy (LA-ART) could potentially improve outcomes in particular for those HIV-infected individuals with poor daily ART adherence. In this study the clinical role and cost-effectiveness of 3 long-acting ART strategies (LA-ART for patients with multiple ART failures; second-line LA-ART for those failing first-line therapy; and first-line LA-ART for ART-naive patients) are compared to daily oral ART using a microsimulation model.   

The findings of this study showed that LA-ART could improve survival of HIV patients in the United States, especially those with poor daily ART adherence. At an annual drug cost of $48,000, LA-ART will be cost-effective in patients with multiple ART failures. The authors also state that in order for LA-ART to be a viable option for first- or second-line therapy, its cost must approach that of currently available regimens.

 

Source:

Ross EL, Weinstein MC, Schackman BR et al. The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases 2015; 60 (7): 1102-1110. https://doi.org/10.1093/cid/ciu1159